Podcasts about Head and neck cancer

Show notes and links:  www.chrisbeatcancer.com/how-juanita-cummings-healed-head-and-neck-cancer-naturally

In this episode,  Aarti Bhatia, MD, MPH, and  Deborah J. Wong, MD, PhD, discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing considerations, and future precision oncology approaches for HPV-positive and HPV-negative patients with head and neck cancer. Presenters: Aarti Bhatia, MD, MPH Associate Professor of Medicine (Medical Oncology) Clinical Research Team Leader, Head and Neck Cancers Program Yale Cancer Center New Haven, Connecticut Deborah J. Wong, MD, PhD Director, Head and Neck Medical Oncology Program Associate Clinical Professor of Medicine Division of Hematology/Oncology University of California, Los Angeles (UCLA) Los Angeles, California Link to full program: https://bit.ly/49kViqg Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Interview with Baran D. Sumer, MD, and Lauren Gabra, MD, authors of Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer. Hosted by Paul C. Bryson, MD, MBA. Related Content: Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

Interview with Baran D. Sumer, MD, and Lauren Gabra, MD, authors of Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer. Hosted by Paul C. Bryson, MD, MBA. Related Content: Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

- Overview of Oral, Head & Neck Cancer, Including Staging & Diagnosing - Surgical Interventions, Including Plastic & Reconstructive Surgery - The Difference Between HPV Positive and HPV Negative Head and Neck Cancer Diagnoses - New Chemotherapy Options - Concurrent Chemotherapy & Radiotherapy - Key Questions in Making Treatment Decisions - The Role of Clinical Trials: How Research Increases Your Treatment Options - Managing Side Effects, Symptoms, Discomfort, & Pain - Guidelines & Tips for the Care of Your Teeth, Gums, & Mouth - Speech and Swallowing Rehabilitation - Nutrition & Hydration Concerns & Tips - The Importance of Communicating with Your Health Care Team: Key Questions to Ask About Your Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Oral, Head & Neck Cancer, Including Staging & Diagnosing - Surgical Interventions, Including Plastic & Reconstructive Surgery - The Difference Between HPV Positive and HPV Negative Head and Neck Cancer Diagnoses - New Chemotherapy Options - Concurrent Chemotherapy & Radiotherapy - Key Questions in Making Treatment Decisions - The Role of Clinical Trials: How Research Increases Your Treatment Options - Managing Side Effects, Symptoms, Discomfort, & Pain - Guidelines & Tips for the Care of Your Teeth, Gums, & Mouth - Speech and Swallowing Rehabilitation - Nutrition & Hydration Concerns & Tips - The Importance of Communicating with Your Health Care Team: Key Questions to Ask About Your Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts

Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study." LINK TO FULL TRANSCRIPT

This episode features Dr Catriona Mayland (University of Sheffield, UK. Sheffield Teaching Hospitals NHS Foundation Trust, UK. Palliative Care Unit, University of Liverpool, UK).   What is already known on this topic? The disease trajectory for people with incurable head and neck cancer is unpredictable. This cancer subgroup has high healthcare utilisation even in the last months of life.   What this paper adds Patients, caregivers and healthcare professionals consistently reported systemic variability in healthcare experiences for those with incurable head and neck cancer. Improving access to symptom relieving medications, helping more with advocacy, and developing ways to improve caregivers' preparedness reflect areas for improvement across the disease trajectory. Information needs change over time, with initial overload, but then complexities relating to advance care planning developing later due to the unpredictable nature of the disease.   Implications for practice, theory or policy Solutions include cancer centres adopting more accessible, inclusive means of communication and providing patients and families with reliable contact points for key healthcare professionals. Developing strategies or interventions to improve caregivers' preparedness should incorporate both caregivers and relevant healthcare professionals to ensure the technical aspects of care can be addressed.   Full paper available from:     https://journals.sagepub.com/doi/10.1177/02692163261416267   If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu:  a.nwosu@lancaster.ac.uk

Send us Fan MailDr. Madia Russillo, otolaryngologist with Physicians' Clinic of Iowa Ear, Nose & Throat, joins Dr. Arnold to discuss the signs, symptoms and risk factors of head and neck cancer, as well as how the HPV vaccine plays an important role in preventing it.For more information on ENT services provided at PCI call (319) 399-2022. For more information on services and resources available for cancer patients, call (319) 558-4876 or visit communitycancercenter.org If you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

In this special rebroadcast, we honor the memory of Kelly U'Ren Moody, a devoted advocate and colleague who passed away on January 16, 2026. This conversation, originally recorded in September 2021, captures Kelly's extraordinary spirit as she navigated a terminal oral cancer diagnosis. After being told in 2016 that she had only four to six months to live, Kelly went on to live a full, impactful life for nearly another decade.Kelly's story is a testament to the power of gratitude and the unfiltered reality of long-term survivorship. She shares how she transitioned from a career in finance to health coaching just as her diagnosis changed her life, and how she chose to "face it head-on" every single day.In this Episode:Navigating the TerminalThe Reality of Side EffectsThe Power of GratitudeCommunicating with Loved OnesTranscript: https://bit.ly/podscript181About Kelly: Kelly was the creator of the blog Face It Head On, where she shared her journey with head and neck cancer to provide hope to others worldwide. Her legacy lives on through the lives she touched and the advocacy work she championed within the cancer community.Visit Kelly's SocialsFacebook: https://www.facebook.com/KellyURenMoodyLinkedIn: https://www.linkedin.com/in/kellyurenmoody/Instagram: https://www.instagram.com/kellyurenmoo/Book: https://a.co/d/09KgBORmOriginal recording: https://podcast.ausha.co/navigatingcancertogether/living-looking-beyond-6-monthsVideo: The Fight of my Life, https://youtu.be/DmcXbbUDzykSupport the Podcast: If this episode resonated with you, please consider sharing it with someone who needs a dose of hope today. You can also rate and review Navigating Cancer TOGETHER on Apple Podcasts or Spotify to help more people find these stories.Connect & Engage with Talaya: https://solo.to/cancerdoula

This week, Bobbi Conner talks with MUSC's Ashton Getchell about follow up care for head and neck cancer survivors after completing active cancer treatment.

In this episode of CURiE Conversations on the ACRO Podcast, Dr. Veronia Fahmy speaks with author Dr. Ricky Savjani about his published article, “A Silicone-Based Film-Forming Gel Wound Dressing for Radiation Dermatitis in Head and Neck Cancer Patients: A Retrospective Cohort Analysis Using Clinical Informatics.”Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/421775-a-silicone-based-film-forming-gel-wound-dressing-for-radiation-dermatitis-in-head-and-neck-cancer-patients-a-retrospective-cohort-analysis-using-clinical-informatics#!/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

In this episode of Onc Now, Kevin Harrington discusses the evolving landscape of head and neck cancer treatment, from the transformative impact of immunotherapy to the promise of oncolytic viruses. He reflects on the challenges that defined a decade of limited progress, the integration of radiotherapy and systemic therapies, and the importance of translating innovative science into clinical benefit. With insights into salivary gland cancers, combination strategies, and advice for the next generation of oncologists, this episode offers a comprehensive look at one of oncology's most rapidly advancing fields.  Timestamps:  00:00 – Introduction  01:10 – Specialisation in head and neck cancers  03:39 – Biggest challenges   06:30 – Impact of radiotherapy   11:19 – Role of systemic therapy  16:13 – Immunotherapy   21:10 – Salivary gland cancers  28:34 – Viruses as anti-cancer agents  33:22 – Translating innovative science  38:00 – Pairing viruses for certain cancers  41:47 – Advice to young oncologists  44:29 – Important breakthroughs  47:21 – Three magic wishes 

"It's important to clarify that most patients will experience and at least some side effects—and often several. So prevention really means reducing severity, complications, and long-term impact rather than avoiding side effects altogether. This process starts before radiation begins and continues throughout the treatment and includes dental evaluation, baseline swallowing assessments, and thorough patient education," ONS member Astrid Amoresano, RN, OCN®, lead oncology nurse specialist at New York Proton Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about side effects of radiation for head and neck cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 13, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to radiation side effects in people with head and neck cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Cancer Symptom Management Basics series Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 128: Manage Treatment-Related Radiodermatitis With ONS Guidelines™ ONS Voice articles: Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education IMRT Shows Similar Quality-of-Life Outcomes to Proton Therapy in Head and Neck Cancer How to Handle Even the Worst Radiation Therapy Side Effects ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ ONS Oncology Symptom Management Clinical Journal of Oncology Nursing articles: The Role of Advanced Practice Providers in Radiation Oncology in 2025 Systematic Review of Malnutrition Risk Factors to Identify Nutritionally At-Risk Patients With Head and Neck Cancer Effects of a Nurse-Initiated Telephone Care Path for Pain Management in Patients With Head and Neck Cancer Receiving Radiation Therapy Radiation-Induced Skin Dermatitis: Treatment With CamWell® Herb to Soothe® Cream in Patients With Head and Neck Cancer Receiving Radiation Therapy ONS Radiation Learning Library ONS Symptom Intervention Resources ONCC: Radiation Oncology Certified Nurse (ROCN™) American Cancer Society CA: A Cancer Journal for Clinicians article: American Cancer Society Head and Neck Cancer Survivorship Care Guideline Cancer Survivors Network: Head and neck cancer Head and neck cancer resources Radiation therapy resources American Society of Radiation Oncology National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many tumors in the region are very radiosensitive, and radiation can be used either as definitive treatment or after surgery to reduce the risk of reoccurrence, but in many cases, radiation is combined with chemotherapy to improve local control. Because so many vital structures are located in this small complex area, radiation allows us to treat the cancer while minimizing the need for extensive or disfiguring surgery." TS 2:40 "The most common acute side effects of head and neck radiation: effects to the mouth, the throat, the skin, and the energy level. Patients often experience a mucositis, pain or sore throat, difficulty swallowing, dry mouth, or thick saliva, and taste changes. Skin irritation and redness in the treatment field is also common and can progress to dry and moist desquamation. Fatigue is another frequent side effect and tends to build as treatment progresses. Emotional and psychological distress are also very common in this patient population and can have an impact on daily function and quality of life. Side effects usually develop gradually, often beginning in the second and third week of radiation and may be more severe or have an earlier onset in patients receiving concurrent chemotherapy." TS 4:02 "Pain management is essential so patients can continue eating and drinking. Supporting the energy level and maintaining hydration are also key, as fatigue and dehydration can significantly worsen other side effects. Oral care protocols help manage mucositis and nutrition support may include supplements or enteral feeding if needed." TS 11:24 "Sexual health might not be the first thing nurses think of in regard to head and neck radiation. … But even though radiation for head and neck cancer doesn't involve the reproductive organs, it can still have a significant impact on sexual health and intimacy. Like fatigue, pain, dry mouth, changes in speech and visible changes in appearance can all affect body image and relationships." TS 14:52 "One of the common misconceptions is that side effects end when radiation ends. In reality, some effects peak afterward or become long term. Xerostomia, or dry mouth, and taste changes are good examples. While some patients improve, others adjust to a new normal where dry mouth and altered taste are permanent." TS 19:53

Today's guest is Jonathan Gegerson, author, speaker, and advocate for those diagnosed with cancer. Jonathan was diagnosed in 2019 with very rare salivary duct carcinoma and has endured over 200 chemo cycles, 67 radiation sessions and 7 major surgeries over the past 6 years. His goal is to inspire others to be thankful for what they have, help them embrace the suffering and turn it into victory. He recently published Perspective C, sharing the power of words, time, love, and suffering.We talk about how cancer can affect even the healthiest people, the importance of second opinions, facing recurrences with positivity and humor, the marathon vs. sprint journey of cancer, putting things in perspective, and so much more!Jonathan is one of the most positive people I've ever met and his outlook on life is so inspiring. What a conversation to kick off 2026!Resources:More of Jonathan's Story: https://breakingcancernews.com/2025/10/13/salivary-duct-carcinoma-treatments-are-evolving-and-dentists-can-help/Jonathan's Book Perspective C: https://a.co/d/37WWbY0Jonathan's Email: jonathangegerson@gmail.comFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QME865. CME/MOC/AAPA/IPCE credit will be available until December 12, 2026.Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QME865. CME/MOC/AAPA/IPCE credit will be available until December 12, 2026.Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QME865. CME/MOC/AAPA/IPCE credit will be available until December 12, 2026.Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QME865. CME/MOC/AAPA/IPCE credit will be available until December 12, 2026.Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QME865. CME/MOC/AAPA/IPCE credit will be available until December 12, 2026.Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QME865. CME/MOC/AAPA/IPCE credit will be available until December 12, 2026.Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Send us a textMore than 72,500 people in the U.S. were estimated to be diagnosed with three types of head and neck cancer in 2025. Of those, more than 16,500 were estimated to die from these diseases. Joehassin Cordero, M.D., a Texas Tech Physicians head and neck surgeon and chair of the department of otolaryngology, is our guest expert for this episode. Dr. Cordero lists the different cancers considered head and neck cancers, possible causes, symptoms and treatment and patients are at risk for secondary cancers.

Send us a textIn our update this month Derek Munn, Director of Policy and Public Affairs at the RCSLT covers:Big news from 2025, including RCSLT successes such as the Invest in SLT debate, Voicebox competition in Scotland, Language Launchpad and launch of AHPF Cymru in Wales; the budget in England.Lots happening in Scotland around children and young people. RCSLT particularly welcomes the 'Early years speech, language and communication action plan': https://www.gov.scot/publications/speech-language-communication-action-plan/Best Start Family Hubs in England to be a one-stop shop for parents of children with SEND.Publication of the 'Getting it right first time' head and neck cancer report: https://gettingitrightfirsttime.co.uk/medical_specialties/head-and-neck-cancer/The House of Lords committee on the Autism Act has highlighted speech, language, and communication, the role of speech and language therapy, and the barriers too many autistic people, of all ages, and their families face accessing it, across education, employment, health, justice, and social care The Office of the Chief Allied Health Professions Officer (CAHPO) at NHS England has commissioned NHS Elect to co-produce  a Transformation Toolkit for NHS community speech and language therapy services for children and young people https://www.rcslt.org/news/toolkit-to-support-nhs-services-to-reduce-waiting-times-for-children-and-young-people/ Please be aware that the views expressed are those of the guests and not the RCSLT.Please do take a few moments to respond to our podcast survey: uk.surveymonkey.com/r/LG5HC3R

Head and neck cancer is the seventh most common cancer worldwide and is commonly associated with tobacco and alcohol use, or human papillomavirus (HPV) infection. Author Lara Dunn, MD, of Memorial Sloan Kettering Cancer Center joins JAMA Associate Editor Margaret Wheeler, MD, to discuss the epidemiology, risk factors, diagnosis, treatment, and prognosis of head and neck cancer. Related Content: Head and Neck Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

In 2019, Jonathan Gegerson sought medical attention went he felt a lump on the right side of his neck.  After a couple of scans and a biopsy, he was diagnosed with salivary duct carcinoma, a rare form of head and neck cancer.  Jonathan survived, but not before enduring 67 sessions of radiation, 12 cycles of chemotherapy (carboplatin, taxol, herceptin) and seven surgeries.  He still undergoes a targeted therapy on a monthly basis, and the surgery has affected his speech and his diet, but Jonathan has resumed an active lifestyle that includes skiing and hiking.   Jonathan Gegerson thought his health was outstanding.  He was an active skier and liked to hike up Colorado's 14ers (mountains whose peaks exceed 14,000 feet), but was perplexed when he discovered a lump on the right side of his neck.   He did not waste any time seeking medical attention and went to his primary care physician.  She conducted a physical examination and asked if Jonathan had recently undergone a root canal or some dental procedure that could result in an infection.  When he said no, the doctor sent Jonathan to an oncologist, who called for a CT scan, a PET scan and a biopsy.  That's when he was diagnosed with head and neck cancer, even though at the time doctors could not specify what type of head and neck cancer.   His doctor in Colorado said Jonathan would need to undergo surgery, followed by radiation treatment and chemotherapy.  When Jonathan learned his care team had no experience with dealing with his type of cancer, he sought a second opinion from MD Anderson in Houston, Texas.  The doctors at MD Anderson suggested the same regimen, but Jonathan switched to them because they had experience dealing with salivary duct carcinoma.   His care team told him his treatment would result in a tightening of his face and would affect his speech, in addition to his ability to chew and swallow.   The chemotherapy regimen included carboplatin, taxol and herceptin.  He said the chemo left him weak and tired, especially two days after each round of treatment.  This, he said, was very frustrating because he was accustomed to being active.  During this time, the best he could do was go on short walks.   When Jonathan experienced a recurrence, he was placed on a targeted therapy of kadcyla and herceptin.  He eventually achieved survivorship but must continue to be on a monthly targeted therapy of unhertu and herceptin.   Jonathan Gegerson says his health is approximately 75 percent of what it was before his diagnosis, but he feels he blessed that he is living, is back to hiking and skiing, and hopes to continue skiing until he is 90 years old.   Additional Resources: Jonathan's Book: "Perspective C," available on Amazon and Kindle  https://a.co/d/4iW9BQ6      

Host Polly Swingle is joined by Speech-Language Pathologist, Chrissy Regan, M.A., CCC-SLP, to talk about the benefits of working with a Speech and Language Pathologist for those with head and neck cancer. Chrissy breaks down what head and neck cancer is, causes of this type of cancer, and effective treatments for those who have been diagnosed.Chrissy Regan, M.A., CCC-SLP, earned her Bachelor of Applied Arts in Communication Disorders (2010) and Master of Arts in Speech-Language Pathology (2013) from Central Michigan University. She joined The Recovery Project in February 2025 after working for 10 years in a Michigan-based outpatient rehabilitation clinic, where she developed a head and neck cancer program focused on improving speech and swallowing outcomes for patients undergoing chemotherapy and radiation therapy. Chrissy is certified in Lee Silverman Voice Treatment (LSVT LOUD) and SpeakOut! therapy programs for the treatment of Parkinson's Disease and she specializes in adult neurological disorders. She also holds a certification in VitalStim® therapy, an evidence-based approach for the treatment of swallowing disorders. Chrissy is also a part of the Concentrated Stroke Rehabilitation team at The Recovery Project.Learn more about The Recovery Project! View our website at www.therecoveryproject.net Call us 855-877-1944 to become a patient Follow us on Instagram Like us on Facebook Thanks for listening!

Brandon Prendes, MD joins this episode of Head & Neck Innovations to discuss the upcoming 2025 Contemporary Multidisciplinary Care of the Head and Neck Cancer Patient course. The course provides a contemporary update of management strategies for head and neck cancer, using a multidisciplinary approach.

The FDA approved lenacapavir, a twice-yearly injectable PrEP shown to be 99% effective in preventing HIV, though high cost may limit global access. A phase 3 trial found that adding pembrolizumab to standard care improved event-free survival in head and neck cancer, especially in patients with high PD-L1 expression. MASLD-related deaths in the U.S. have quadrupled since 2006, rising most sharply in older adults and rural areas, and are expected to continue increasing.

Interview with Leila J. Mady, MD, PhD, MPH, author of Longitudinal Financial Toxicity and Quality of Life in Head and Neck Cancer. Hosted by Paul C. Bryson, MD, MBA. Related Content: Longitudinal Financial Toxicity and Quality of Life in Head and Neck Cancer

What does it take to improve quality of life after head and neck cancer? In this episode of Backtable ENT, guests Dr. Heather Starmer, a speech and language pathologist at Stanford University, and Dr. Michael Moore, a head and neck cancer surgeon at Indiana University explore the topic of head and neck cancer survivorship.---SYNPOSISThe discussion centers on the multifaceted challenges faced by survivors, including dysphagia, dry mouth, chronic pain, and mental health issues. The experts emphasize the importance of early intervention, community support, and comprehensive care to enhance the quality of life for survivors. Various resources, such as the Head and Neck Cancer Alliance, are highlighted to assist patients and providers in navigating survivorship. The conversation also outlines future directions in research and the need for more qualitative studies to better understand long-term survivorship outcomes.---TIMESTAMPS00:00 - Introduction03:23 - Understanding Survivorship & Challenges in Head and Neck Cancer14:06 - Managing Mobility and Lymphedema18:47 - Addressing Chronic Pain and Mental Health21:37 - Dental Care and Trismus Therapy25:58 - Long-Term Survivorship and Quality of Life31:36 - Survivorship Clinics and Multidisciplinary Care34:39 - Resources for Patients and Providers38:49 - Future Research and Educational Gaps---RESOURCESDr. Heather Starmerhttps://med.stanford.edu/profiles/heather-starmerDr. Michael Moorehttps://iuhealth.org/find-providers/provider/michael-g-moore-md-64028

Patient Jon Bohnsack understands endurance. A different kind of endurance was tested when doctors discovered head and neck cancer. Learn about his treatments that didn't even require surgery.

Dr. Deepak Kademani discusses how to successfully host an oral cancer screening event – from planning to community outreach – and shares insights on the importance of early detection.

Human Papillomavirus, or HPV, is a virus that infects the skin and wet surfaces of the body. It's a disease that's commonly spread through sexual activity, and over 80% of people will get it at some point in their lifetime. HPV is an endemic disease, which, in epidemiology, means that it is constantly present in a particular population. While most people recover from HPV, there can be complications. It is responsible for more than 90% of anal and cervical cancers and can also cause oropharyngeal cancer. Dr. Wu, a board-certified otolaryngologist, specializes in head and neck surgical oncology. Diseases like HPV and cancers that affect the head and neck are what she sees most in her patients. Working closely with other multispecialty experts at PNI, Dr. Wu is committed to guiding her patients through their cancer journeys. Listen in.

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Melina Windon, MD,  Assistant Professor of Otolaryngology, UK Markey Cancer Center Cancer Conversations Episode 63 In this episode of Cancer Conversations on Talking FACS, Dr. Melina Windon, an Assistant Professor of Ear, Nose and Throat Surgery at the University of Kentucky Markey Cancer Center, discusses head and neck cancers. Dr. Windon provides insights into her specialty, emphasizing the critical aspects of cancer diagnosis, treatment, and reconstructive surgery, which restores patients' ability to speak and swallow. Listeners will gain valuable knowledge about the primary risk factors for head and neck cancer, including tobacco use, HPV exposure, and heavy alcohol consumption. Dr. Windon highlights the importance of the HPV vaccine as a preventive measure, particularly targeting both boys and girls at a young age. She also explains the significance of routine oral cancer screenings and early detection of symptoms like persistent spots or lumps in the mouth or neck. The episode underscores the higher incidence and mortality rates of head and neck cancer in Kentucky, stressing the urgency for awareness and timely medical intervention. Tune in to learn more about preventing and managing these formidable cancers and the role of groundbreaking reconstructive surgery in restoring quality of life for affected individuals. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On X @UKMarkey